Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes-Reference-Cited by-同舟云学术

Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes

Published:2023-09 Issue:9 Volume:37 Page:108588
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Krämer Bernhard K.^ORCID,Hauske Sibylle J.^ORCID,Chilton Robert^ORCID,Mann Johannes F.E.^ORCID,Gullestad Lars^ORCID,Fitchett David^ORCID,Mattheus Michaela^ORCID,Steubl Dominik^ORCID,Wanner Christoph^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference32 articles.

1. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial;Fitchett;Eur Heart J,2016

4. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

5. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial;Perkovic;Nephrol Dial Transplant,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review;Cureus;2024-09-03

2. Effects of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data;Medicina;2024-07-24

3. Diabetes mellitus and heart disease;Metabolism and Target Organ Damage;2024-04-09

4. Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus;Journal of Diabetes and its Complications;2023-12